In melanoma, G9 synergizes with a BRAF inhibitor and an MEK inhibitor to enhance apoptosis signaling, increase sensitivity to targeted therapies, reverse resistance to vemurafenib in vitro, and reduce tumor growth in vivo [43]. This evidence concerns the gene BRAF and neoplasm.